Anti-pandemic vaccine backed by RCGP

The DoH should consider vaccinating all patients in at-risk groups with a pre-pandemic H5N1 vaccine to help protect against an influenza pandemic, the RCGP has advised.

The call comes after GlaxoSmithKline received the first positive opinion from the European Medicines Agency for the use of its H5N1 pre-pandemic vaccine, Prepandrix.

Results from a series of clinical trials have shown that Prepandrix can offer protection against a number of H5N1 variant strains currently circulating. 

Dr George Kassianos, RCGP immunisation spokesman and Berkshire GP, welcomed the decision to approve Prepandrix for use against an influenza pandemic.

‘The threat of a pandemic is very real, so we need to be prepared for it.'

sanjay.tanday@haymarket.com

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus